Table of Contents 3
List of Tables 5
List of Figures 5
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lipocine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lipocine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Lipocine Inc, Pharmaceuticals & Healthcare, Deal Details 11
Merger 11
Marathon Bar And Lipocine Complete Reverse Merger Transaction 11
Licensing Agreements 12
Lipocine Enters into Licensing Agreement with Spriaso 12
Equity Offering 13
Lipocine Plans to Raise up to USD10.8 Million in Public Offering of Shares 13
Lipocine to Raise USD20 Million in Public Offering of Shares 14
Lipocine Raises USD34.8 Million in Public Offering of Common Stock 15
Lipocine Completes Underwriters Exercise Of Full Over-Allotment Option Of Public Offering Of Shares For US$14.2 Million 17
Lipocine Completes Private Placement Of Shares For US$37.8 Million 18
Lipocine Inc - Key Competitors 19
Lipocine Inc - Key Employees 20
Lipocine Inc - Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Aug 07, 2018: Lipocine announces financial and operational results for the second quarter and six months ended June 30, 2018 22
May 07, 2018: Lipocine Reported Financial and Operational Results for the First Quarter Ended March 31, 2018 24
Mar 12, 2018: Lipocine Reports Financial and Operational Results for the Fiscal Year Ended December 31, 2017 25
Nov 08, 2017: Lipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017 26
Aug 07, 2017: Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2017 27
May 08, 2017: Lipocine Announces Financial and Operational Results for the First Quarter 2017 29
Mar 06, 2017: Lipocine Announces Financial and Operational Results for the Full Year of 2016 30
Corporate Communications 31
Feb 15, 2017: Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer 31
Legal and Regulatory 32
Feb 16, 2018: Lipocine Announces Settlement of Securities Class Action Lawsuit 32
Sep 21, 2017: Lipocine Announces Motions Decision by USPTO in Interference Against Clarus 33
Product News 34
06/19/2017: Lipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Dosing Validation and Dosing Flexibility Studies of LPCN 1021 34
06/19/2017: Lipocine Validates "No Titration"Dosing Regimen With Positive Topline Efficacy Results for LPCN 1021, Oral Testosterone Candidate 35
Product Approvals 36
May 09, 2018: Lipocine Receives Complete Response Letter for TLANDO From U.S. Food and Drug Administration 36
Jan 10, 2018: Lipocine Announces Outcome of FDA Advisory Committee Meeting for TLANDO, Testosterone Replacement Therapy in Adult Males with Hypogonadism 37
Nov 17, 2017: U.S. FDA Extends Review for TLANDO; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged 38
Oct 18, 2017: FDA Advisory Committee Scheduled to Review TLANDO on January 10, 2018 39
Sep 20, 2017: Lipocine Announces FDA Advisory Committee Meeting for TLANDO 40
Aug 14, 2017: Lipocine Announces FDA Acknowledgement of TLANDO (“LPCN 1021”) NDA Resubmission; PDUFA Goal Date, February 8, 2018 41
Aug 09, 2017: Lipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism 42
Clinical Trials 43
Jun 07, 2018: Lipocine Announces Dosing in Ambulatory Blood Pressure Study for TLANDO 43
Apr 24, 2017: Lipocine Completes Enrollment in the LPCN 1021 Fixed Dose Clinical Trials 44
Jan 05, 2017: Lipocine Initiates a Dosing Flexibility Study for LPCN 1021, Its Oral Testosterone Replacement Product Candidate 45
Other Significant Developments 46
Feb 08, 2018: Lipocine Announces $10 Million Loan and Security Agreement with Silicon Valley Bank 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Lipocine Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lipocine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lipocine Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Lipocine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Marathon Bar And Lipocine Complete Reverse Merger Transaction 11
Lipocine Enters into Licensing Agreement with Spriaso 12
Lipocine Plans to Raise up to USD10.8 Million in Public Offering of Shares 13
Lipocine to Raise USD20 Million in Public Offering of Shares 14
Lipocine Raises USD34.8 Million in Public Offering of Common Stock 15
Lipocine Completes Underwriters Exercise Of Full Over-Allotment Option Of Public Offering Of Shares For US$14.2 Million 17
Lipocine Completes Private Placement Of Shares For US$37.8 Million 18
Lipocine Inc, Key Competitors 19
Lipocine Inc, Key Employees 20
Lipocine Inc, Other Locations 21

List of Figures
Lipocine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lipocine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9